The company's proprietary reformulations of existing drugs address major unmet needs in the field of Parkinson's disease and central nervous system disorders, enabling continuous, controlled administration primarily subcutaneously or transdermally, resulting in enhanced clinical efficacy and improved quality of life for patients.